PARIS: Sanofi announced the acquisition of 2.3% of its shares from long-term shareholder L’Oréal as part of its share buyback program initiated on Jan. 30, 2025. The move aligns with Sanofi’s capital allocation strategy and commitment to sustainable value creation for shareholders. “L’Oréal has been a trusted shareholder and partner for decades, playing a key…
PARIS, FRANCE: Sanofi, a global leader in healthcare, announced today its financial results for the year 2023, showing a 5.3% increase in sales and a 5.4% increase in business earnings per share (EPS) at constant exchange rates (CER). The company attributed its solid performance to the successful launches and growth of its specialty care products,…
PARIS, FRANCE: Sanofi, a global pharmaceutical company, has agreed to acquire Inhibrx, a clinical-stage biotech firm, for $30.0 per share in cash, or about $1.7 billion. The deal is subject to the spin-off of non-INBRX-101 assets into a new entity, New Inhibrx, which will be owned by Inhibrx’s shareholders and Sanofi. INBRX-101 is a novel…
PARIS, FRANCE: Sanofi, a global biopharmaceutical company, announced today the appointment of three new members to its Executive Committee and the departure of one of its senior leaders. Houman Ashrafian, a renowned scientist and investor, will join Sanofi as Head of Research & Development, starting September 11th, 2023. He will be responsible for advancing Sanofi’s…
PARIS, FRANCE: Sanofi announced today that it has entered into a definitive agreement to acquire ownership of Qunol, a U.S.-based, market-leading brand in health & wellness, focusing on the active ‘healthy aging’ segment. Qunol offers CoQ10 and Turmeric products that support heart health and joint health, respectively. These products are backed by science literature and…
PARIS, FRANCE: Sanofi has entered into an agreement to acquire Amunix Pharmaceuticals Inc, an immune-oncology company. Amunix’s pipeline, which includes lead candidate, AMX-818, a masked HER2-directed TCE, offers a strong strategic fit with Sanofi’s focus on developing potentially transformative cancer therapies in immuno-oncology. Under the terms of the agreement, Sanofi will acquire Amunix Pharmaceuticals for…
VIENNA, AUSTRIA: Sanofi has entered into an agreement to acquire Origimm Biotechnology GmbH, a news release said. Origimm Biotechnology is an Austrian privately owned biotechnology company specializing in the discovery of virulent skin microbiome components and antigens from bacteria causing skin disease, such as acne. With this acquisition, Sanofi continues executing its global Play to…
PARIS, FRANCE: Sanofi announced an equity investment of $180 million and a new strategic collaboration with Owkin comprised of discovery and development programmes in four exclusive types of cancer, with a total payment of $90 million for three years plus additional research milestone-based payments, a news release said. Owkin, an artificial intelligence (AI) and precision…
LONDON, UK: Sanofi, a global biopharmaceutical company, has committed to invest up to $60 million in equity of Gyroscope Therapeutics Holdings. Gyroscope plans to use proceeds from this investment to support funding of ongoing clinical trials of GT005 in GA. GT005 has been granted Fast Track designation by the U.S. Food and Drug Administration and…
PARIS: Sanofi announced a €400 million investment over five years to create a unique vaccine production center in Singapore. In partnership with the Singapore Economic Development Board (EDB), the new site will mainly supply the Asian region and complement existing manufacturing capacities in Europe and North America. The investment furthers Sanofi’s commitment to driving the…
LONDON: Schroder UK Public Private Trust (SUPP) has sold of its shares in Kymab Group Ltd. to Sanofi against initial proceeds of approximately US$82 million. Furthermore, the SUPP has the potential for additional contingent payments of up to US$33 million subject to a deferred purchase price release and Kymab achieving certain development and regulatory milestones….
PARIS: Sanofi, Capgemini, Generali and Orange are forming a joint venture in France to fast-track the development of concrete healthcare solutions and to make them available to the market for the benefit of patients, a news release said. The project, on a scale that is unique in Europe, will bring together leading scientific and technological…